DK2298314T3 - Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse - Google Patents

Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse Download PDF

Info

Publication number
DK2298314T3
DK2298314T3 DK10010211.0T DK10010211T DK2298314T3 DK 2298314 T3 DK2298314 T3 DK 2298314T3 DK 10010211 T DK10010211 T DK 10010211T DK 2298314 T3 DK2298314 T3 DK 2298314T3
Authority
DK
Denmark
Prior art keywords
dosage unit
analog
dose
constipation
formula
Prior art date
Application number
DK10010211.0T
Other languages
English (en)
Inventor
Ryuji Ueno
Myra L Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2298314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK2298314T3 publication Critical patent/DK2298314T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Claims (12)

1. Doseringsenhed til anvendelse i lindring eller forebyggelse af forstoppelse hos en human patient omfattende en prostaglandin (PG)-analog som vist med formel (I) og/eller dens tautomerer, og en farmaceutisk egnet excipiens, hvor doseringsenheden indeholder PG-analogen i en mængde i området på ca. 6-72 pg:
formel I hvor Ai og A2 er de samme eller forskellige halogenatomer og B er -COOH, omfattende dens farmaceutisk acceptable salte, estere eller amider, og hvor doseringsenheden administreres tilstrækkelig gange pr. dag så at den totale daglige dosis af PG-analogen er i området på ca. 48-72 pg.
2. Doseringsenheden ifølge krav 1, hvor PG-analogen er en monocyklisk tautomer med formel (I).
3. Doseringsenheden ifølge krav 1 eller 2, hvor Ai og A2 er fluoratomer.
4. Doseringsenheden ifølge et hvilket som helst af kravene 1-3, hvor B er -COOH.
5. Doseringsenheden ifølge et hvilket som helst af kravene 1-4, hvor PG-analogen er til stede i området på ca. 24-72 pg.
6. Doseringsenheden ifølge et hvilket som helst af kravene 1-5, hvor PG-analogen er til stede i området på ca. 48-60 pg.
7. Doseringsenheden ifølge krav 6, hvor PG-analogen er til stede i området på ca. 24-48 pg.
8. Doseringsenheden ifølge krav 7, hvor PG-analogen er til stede ved ca. 24 pg.
9. Doseringsenheden ifølge krav 1, hvor den totale daglige dosis er PG-analogen er ca. 48 pg.
10. Doseringsenheden ifølge et hvilket som helst af kravene 1-9, hvor den farmaceutisk egnede excipiens er oralt acceptabel.
11. Doseringsenheden ifølge et hvilket som helst af kravene 1-9, hvor den farmaceutisk egnede excipiens er et fedtsyretriglycerid med medium kæde.
12. Doseringsenhed omfattende en prostaglandin (PG)-analog som vist med formel (I) og/eller dens tautomerer, og en farmaceutisk egnet excipiens, hvor doseringsenheden indeholder PG-analogen i en mængde på ca. 24 pg:
formel I hvor Ai og A2 er fluoratomer og B er -COOH, omfattende dens farmaceutisk acceptable salte, estere eller amider.
DK10010211.0T 2001-11-14 2002-11-14 Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse DK2298314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
EP02780083A EP1443938B1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
DK2298314T3 true DK2298314T3 (da) 2014-12-01

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02780083.8T DK1443938T3 (da) 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
DK10010211.0T DK2298314T3 (da) 2001-11-14 2002-11-14 Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02780083.8T DK1443938T3 (da) 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse

Country Status (15)

Country Link
US (3) US8097653B2 (da)
EP (2) EP1443938B1 (da)
JP (2) JP4852229B2 (da)
AR (3) AR037524A1 (da)
AT (1) ATE522218T1 (da)
BR (1) BR0214075A (da)
CA (1) CA2464420C (da)
CY (1) CY1115856T1 (da)
DK (2) DK1443938T3 (da)
ES (2) ES2524369T3 (da)
HK (1) HK1155649A1 (da)
LU (1) LU92826I2 (da)
PT (2) PT1443938E (da)
TW (1) TWI331920B (da)
WO (1) WO2003041716A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
CA2502439C (en) * 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
AU2003292556B2 (en) * 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US8026393B2 (en) * 2006-01-24 2011-09-27 Sucampo Ag Soft-gelatin capsule formulation
MX2008009652A (es) 2006-01-24 2008-11-06 R Tech Ueno Ltd Composicion farmaceutica que comprende un compuesto biciclico y metodo para estabilizar el compuesto biciclico.
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
NZ598783A (en) * 2009-09-18 2013-07-26 Adolor Corp Use of opioid receptor antagonist for gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
GB2210556B (en) * 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
DE69130586T2 (de) * 1990-05-01 1999-06-17 R-Tech Ueno, Ltd., Osaka Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
ATE169015T1 (de) * 1992-02-04 1998-08-15 Eisai Co Ltd Aminobenzoesäure derivate
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
CA2279267C (en) 1997-11-28 2010-01-12 R-Tech Ueno, Ltd. Use of 15-ketoprostaglandin e compounds as endothelin antagonist
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
KR100874626B1 (ko) 2000-04-06 2008-12-17 수캄포 아게 담즙 분비 촉진 조성물
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
KR100867295B1 (ko) 2001-05-18 2008-11-06 수캄포 아게 하제 조성물
BR0212233A (pt) 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
AU2003292556B2 (en) 2002-12-27 2009-09-10 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
WO2003041716A1 (en) 2003-05-22
TWI331920B (en) 2010-10-21
CA2464420C (en) 2011-12-13
US8389542B2 (en) 2013-03-05
PT2298314E (pt) 2014-12-03
EP1443938B1 (en) 2011-08-31
ATE522218T1 (de) 2011-09-15
HK1155649A1 (en) 2012-05-25
US20120088824A1 (en) 2012-04-12
CA2464420A1 (en) 2003-05-22
AR098997A2 (es) 2016-06-22
CY1115856T1 (el) 2017-01-25
EP2298314A1 (en) 2011-03-23
TW200300091A (en) 2003-05-16
JP2005513014A (ja) 2005-05-12
JP4852229B2 (ja) 2012-01-11
AR117404A2 (es) 2021-08-04
US20130143958A1 (en) 2013-06-06
PT1443938E (pt) 2011-09-27
AR037524A1 (es) 2004-11-17
US8097653B2 (en) 2012-01-17
LU92826I2 (fr) 2015-11-24
EP2298314B1 (en) 2014-09-03
BR0214075A (pt) 2004-09-28
ES2524369T3 (es) 2014-12-05
US20030119898A1 (en) 2003-06-26
JP2011201905A (ja) 2011-10-13
DK1443938T3 (da) 2011-09-26
ES2368729T3 (es) 2011-11-21
EP1443938A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
US8389542B2 (en) Dosage unit comprising a prostaglandin analog for treating constipation
US8071613B2 (en) Anti-constipation composition
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
JP6408426B2 (ja) 胃腸障害処置用プロスタグランジン誘導体
DE69019431T2 (de) Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
KR20000068996A (ko) 자궁 경관 숙화제
RU2392941C2 (ru) Производные простагландинов для лечения желудочно-кишечного нарушения